相关实验视频

Updated: Feb 28, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

下一代多发性骨髓瘤生物标志物:超越当前指导方针的先进诊断,风险分层和精确治疗

Marta Marques de Carvalho Lopes¹, Laura do Amaral Xavier¹, Silvia Cristina Verde Mendes Nolasco¹

¹Postgraduate Program in Clinical and Toxicological Analysis, Department of Clinical and Toxicology Analysis, College of Pharmacy, Federal University of Minas Gerais, Prof. Moacir Gomes de Freitas Street-Pampulha, Belo Horizonte 31270-901, MG, Brazil.

Pharmaceuticals (Basel, Switzerland)

|February 27, 2026

概括

像ctDNA甲基组和多基组等先进的生物标志物显示出改善多发性骨髓瘤 (MM) 风险分层和治疗的前景. 这些工具可以克服当前的诊断局限性,在血细胞疾病中制定更精确的策略.

科学领域:

瘤血液学瘤血液学
生物标志物发现发现
基因组学和奥米克学

背景情况:

多发性骨髓瘤 (MM) 是一种具有复杂遗传学的血细胞瘤.
非分泌性MM,缺乏单克隆蛋白质分泌,存在诊断挑战.
当前的诊断和治疗模式在精准医学上存在局限性.

研究的目的:

进行对MM的基因组,表观基因组,蛋白质基因组,代谢基因组和放射基因组生物标志物的综合性审查.
评估这些生物标志物的转化潜力和临床限制.
确定当前建议中的差距,并探索未来的方向.

主要方法:

从2018-2025年对文学进行综合叙事审查.
专注于多基因组 (基因组,表观基因组,蛋白质组,代谢组) 和放射性生物标志物.
生物标记物类别的分析,包括ctDNA甲基组,单细胞多组,蛋白组,ex vivo测定和PET/CT放射组.

主要成果:

ctDNA甲基组,单细胞多组,表面抗原蛋白组,ex vivo测定和PET/CT放射组显示出显著的潜力.
这些生物标志物可以增强风险分层,早期进展检测和治疗选择.
确定了超出当前指导框架的新型治疗目标和应用.

结论:

先进的生物标志物平台为血细胞疾病提供了增强的精度策略.
整合这些生物标志物可以克服当前诊断和治疗模型的局限性.
未来的研究应该集中在这些有前途的生物标志物的临床实施上.

关键词:

生物标志物生物标志物多种多种多种多种多种多种多种多种多种多种.多发性骨髓瘤是多发性骨髓瘤的一种疾病.精准医学是一门精准医学.有针对性的治疗.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...